DNTH · Dianthus Therapeutics Inc
United States · RS rating 50 · As of 2026-11-03
| Price | 82.70 USD |
|---|---|
| 1-day change | +0.6% |
| RS rating (overall / 1M / 3M / 12M) | 50 / 43 / 24 / 96 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 31 / 33 / 22 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -47.4% |
| Sales growth Q/Q | -28.3% |
| Distance from 52-week high | +28.7% |
| Market cap (USD) | $4.9B |